本研究旨在確定 MTA 協同 PRMT5 抑制劑 Anvumetostat 與其他治療聯合用於患有轉移性或局部晚期甲基硫代腺苷磷酸化酶（MTAP）缺失胸腔腫瘤的成年受試者時的最大耐受劑量（MTD）或推薦聯合劑量。
適應症：Thoracic Tumors、Non-small Cell Lung Cancer
收案條件
納入條件
- Subprotocol A, B, and C
- Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years).
- Tumor tissue (formalin-fixed, paraffin-embedded sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before Anvumetostat dosing.
- Homozygous MTAP-deletion
- Able to swallow and retain PO administered study treatment.
- Disease measurable as defined by RECIST v1.1.
- Subprotocol A - Histologically or cytologically confirmed diagnosis of NSCLC.
- Arm A (Anvumetostat + carboplatin + paclitaxel + pembrolizumab):
- \- Predominantly squamous histology.
- Arm B (Anvumetostat + carboplatin + pemetrexed + pembrolizumab):
- \- Predominantly non-squamous histology.
- Arm C (Anvumetostat + pembrolizumab):
- \- PD-L1 positive.
- Subprotocol B - Histologically confirmed NSCLC with homozygous MTAP-deletion and KRAS p.G12C mutation.
- Subprotocol C
- Histologically or cytologically confirmed diagnosis of NSCLC with brain metastases.
- Brain lesion meeting RANO-BM criteria for measurable disease.
排除條件
- Subprotocol A, B, and C
- Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis).
- History of solid organ transplant.
- Major surgery within 28 days of first dose of Anvumetostat.
- Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor.
- Radiation therapy within 28 days of first dose.
- Subprotocol A
- \- Autoimmune disease or immunodeficiency disease as defined in the protocol'
收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。